Estimating Public and Patient Savings From Basic Research—A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy

American Journal of Ophthalmology

Volumn 185, Issue , 2018, Pages 115-122

  Windsor, Matthew A ^a   Sun, Sissi J J ^b   Frick, Kevin D ^b   Swanson, Eric A ^c   Rosenfeld, Philip J ^d   Huang, David ^e  

^a Association for Research in Vision and Ophthalmology   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; ARTICLE; COHORT ANALYSIS; COST CONTROL; DRUG COST; HUMAN; INVESTMENT; MEDICARE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REIMBURSEMENT; WET MACULAR DEGENERATION; AGED; ANTAGONISTS AND INHIBITORS; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MEDICAL FEE; PROCEDURES; PUBLIC HEALTH; UNITED STATES;

AGED; ANGIOGENESIS INHIBITORS; COHORT STUDIES; FEE-FOR-SERVICE PLANS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MEDICARE PART B; PUBLIC HEALTH; TOMOGRAPHY, OPTICAL COHERENCE; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 85037697558     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2017.09.027     Document Type: Article

References (45)

1. Kantarjian, H., Rajkumar, S., Why are cancer drugs so expensive in the United States, and what are the solutions?. Mayo Clin Proc 90:4 (2015), 500–504.
2. Swanson E. Estimates of ophthalmic OCT market size and the dramatic reduction in reimbursement payments. OCTnews.org. 2012. Available at http://www.octnews.org/articles/4176266/estimates-of-ophthalmic-oct-market-size-and-the-dr/. Accessed March 1, 2016.
3. Izatt, J.A., Choma, M.A., Theory of optical coherence tomography. Drexler, W., Fujimoto, J.G., (eds.) Optical Coherence Tomography: Technology and Applications, 2008, Springer, Heidelberg, Germany, 47–72.
4. Huang, D., Swanson, E., Lin, C., et al. Optical coherence tomography. Science 254:5035 (1991), 1178–1181.
5. Welzel, J., Optical coherence tomography in dermatology: a review. Skin Res Technol 7:1 (2001), 1–9.
6. Calabresi, P., Balcer, L., Frohman, E., Optical Coherence Tomography in Neurologic Diseases. 2015, Cambridge University Press, Cambridge, Massachusetts.
7. Liang, H., Cid, M., Cucu, R., et al. En-face optical coherence tomography - a novel application of non-invasive imaging to art conservation. Opt Express, 13(16), 2005, 6133.
8. Bezerra, H., Costa, M., Guagliumi, G., Rollins, A., Simon, D., Intracoronary optical coherence tomography: a comprehensive review. JACC Cardiovasc Interv 2:11 (2009), 1035–1046.
9. Tsai, T., Fujimoto, J., Mashimo, H., Endoscopic optical coherence tomography for clinical gastroenterology. Diagnostics 4:2 (2014), 57–93.
10. Nemeth, A., Hannesschlager, G., Leiss-Holzinger, E., Wiesauer, K., Leitner, M., Optical coherence tomography – applications in non-destructive testing and evaluation. Kawasaki, M., (eds.) Optical Coherence Tomography, 2013, INTECH Open Access Publisher, London, UK, 163–185.
11. Ambati, J., Fowler, B., Mechanisms of age-related macular degeneration. Neuron 75:1 (2012), 26–39.
12. Rosenfeld, P., Brown, D., Heier, J., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:14 (2006), 1419–1431.
13. Brown, D., Kaiser, P., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:14 (2006), 1432–1444.
14. Avery, R., Pieramici, D., Rabena, M., Castellarin, A., Nasir, M., Giust, M., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:3 (2006), 363–372.e5.
15. Spaide, R.F., Laud, K., Fine, H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age related macular degeneration. Retina 26:4 (2006), 383–390.
16. Heier, J.S., Brown, D.M., Chong, V., et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:12 (2012), 2537–2548.
17. Medicare Part B Drug Average Sales Price, 2017, Centers for Medicare & Medicaid Services, Washington, DC Available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html. (Accessed 15 July 2017)
18. Erie, J., Barkmeier, A., Hodge, D., Mahr, M., High variation of intravitreal injection rates and medicare anti–vascular endothelial growth factor payments per injection in the United States. Ophthalmology 123:6 (2016), 1257–1262.
19. June 2015 Databook: Health care spending and the Medicare Program, 2015, Medicare Payment Advisory Commission, Washington, DC Available at http://medpac.gov/documents/reports/june-2015-report-to-the-congress-medicare-and-the-health-care-delivery-system.pdf?sfvrsn=0. (Accessed 8 October 2015)
20. Fung, A., Lalwani, G., Rosenfeld, P., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:4 (2007), 566–583.e2.
21. Brown, D., Regillo, C., Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:4 (2007), 627–637.e2.
22. Berg, K., Pedersen, T., Sandvik, L., Bragadóttir, R., Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:1 (2015), 146–152.
23. Wykoff, C., Croft, D., Brown, D., et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration. Ophthalmology 122:12 (2015), 2514–2522.
24. Ying, G., Maguire, M., Daniel, E., et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 122:12 (2015), 2523–2531.e1.
25. Maguire, M., Martin, D., Ying, G., et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Ophthalmology 123:8 (2016), 1751–1761.
26. Ho, A., Busbee, B., Regillo, C., et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121:11 (2014), 2181–2192.
27. Stone, T.W., (eds.) ASRS 2015 Preferences and Trends Membership Survey, 2015, American Society of Retina Specialists, Chicago, IL.
28. Smiddy, W., Economic implications of current age-related macular degeneration treatments. Ophthalmology 116:3 (2009), 481–487.
29. Brechner, R., Rosenfeld, P., Babish, J., Caplan, S., Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare Fee-For-Service Part B claims file. Am J Ophthalmol 151:5 (2011), 887–895.e1.
30. Medicare Provider Utilization and Payment Data: Physician and Other Supplier, 2017, Centers for Medicare & Medicaid Services, Washington, DC Available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Physician-and-Other-Supplier.html. (Accessed 10 July 2017)
31. Gold, M., Jacobson, G., Damico, A., Neuman, T., Medicare Advantage 2015 spotlight: enrollment market update. 2017, The Henry J Kaiser Family Foundation, Menlo Park, CA Available at http://www.kff.org/medicare/issue-brief/medicare-advantage-2015-spotlight-enrollment-market-update/. (Accessed 24 July 2017)
32. Centers for Medicare & Medicaid Services, Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Electronic Reporting Pilot; Inpatient Rehabilitation Facilities Quality Reporting Program; Revision to Quality Improvement Organization Regulations. Fed Regist 77 (2012), 68210–68565.
33. Consumer Price Index, 2017, U.S. Bureau of Labor Statistics, Washington, DC Available at https://www.bls.gov/. (Accessed 20 July 2017)
34. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C., (eds.) Cost-Effectiveness in Health and Medicine, 1996, Oxford University Press, New York.
35. Medicare Physician Fee Schedule Search, 2017, Centers for Medicare & Medicaid Services, Washington, DC Available at https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. (Accessed 20 July 2017)
36. Mittra, R.A., Pollack, J.S., (eds.) ASRS 2008 Preferences and Trends Membership Survey, 2008, American Society of Retina Specialists, Chico, CA.
37. Jumper, J.M., Mittra, R.A., (eds.) ASRS 2012 Preferences and Trends Membership Survey, 2012, American Society of Retina Specialists, Chicago, IL.
38. Part B National Summary Data File (Previously known as BESS), 2017, Centers for Medicare & Medicaid Services, Washington, DC Available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Part-B-National-Summary-Data-File/Overview.html. (Accessed 10 July 2017)
39. NIH Research Portfolio Online Reporting Tools (RePORTER), 2017, National Institutes of Health, Washington, DC Available at https://projectreporter.nih.gov/reporter.cfm. (Accessed 21 July 2017)
40. NSF Award Search, 2017, National Science Foundation, Washington, DC Available at http://www.nsf.gov/awardsearch/simpleSearch.jsp. (Accessed 21 July 2017)
41. Medicare 2016 costs at a glance, 2016, Centers for Medicare & Medicaid Services, Washington, DC Available at https://www.medicare.gov/your-medicare-costs/costs-at-a-glance/costs-at-glance.html#collapse-4809. (Accessed 14 May 2016)
42. What's Medicare Supplement Insurance (Medigap)?, 2016, Centers for Medicare & Medicaid Services, Washington, DC Available at https://www.medicare.gov/supplement-other-insurance/medigap/whats-medigap.html. (Accessed 20 May 2016)
43. Fujimoto, J., Swanson, E., The development, commercialization, and impact of optical coherence tomography. Invest Ophthalmol Vis Sci 57:9 (2016), OCT1–OCT13.
44. Brown, D., Nguyen, Q., Marcus, D., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology 120:10 (2013), 2013–2022.
45. Cheung, N., Wong, I., Wong, T., Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care 37:4 (2014), 900–905.